DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: May 13, 2025

Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation